Drug Trial Radar · NCT04420689
Bevonescein to Highlight Nerves in Patients Undergoing Head & Neck Surgery
Last checked: Nov 19, 2026Latest source record: May 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
27
Actual
Start
Jun 18, 2020
Primary completion
Jun 25, 2021
Study completion Feb 15, 2022
Sponsor
- Lead sponsor
- Alume Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Bevonescein to Highlight Nerves in Patients Undergoing Head \& Neck Surgery
Conditions
- Parotid Neoplasm
- Thyroid Neoplasms
- Head and Neck Neoplasms
- Surgery
- Nerve Injury
- Imaging
Interventions
BevonesceinDrug
Bevonescein Sterile Solution is an intravenously administered, synthetic, peptide dye conjugate indicated for the real-time intraoperative fluorescence detection and localization of nerve tissue.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety - The Number of Patients With ALM-488 Related Adverse EventsTime frame: 28 (+5) days
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
University of California San Diego
San Diego, California
Stanford University
Stanford, California
Harvard-Mass Eye & Ear
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.